Discontinued ProductUnfortunately Methimepip dihydrobromide (Cat. No. 2947) has been withdrawn from sale for commercial reasons.
Extremely selective histamine H3 receptor agonist (pKi values are 9.0, 5.7, < 5.0 and < 5.0 for hH3, hH4, hH1 and hH2 receptors respectively). Potently inhibits EFS-evoked contractions of guinea pig ileum (pD2 = 8.26).
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 341.09. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.93 mL||14.66 mL||29.32 mL|
|5 mM||0.59 mL||2.93 mL||5.86 mL|
|10 mM||0.29 mL||1.47 mL||2.93 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Kitbunnadaj et al (2005) N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J.Med.Chem. 48 2100 PMID: 15771452
View Related Products by Product Action
Keywords: Methimepip dihydrobromide, supplier, selective, H3, agonists, Receptors, Histamine, histaminergic, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience
Citations for Methimepip dihydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for Methimepip dihydrobromide.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.